Kamada Preps for Q2 Financial Results Reveal
Company Announcements

Kamada Preps for Q2 Financial Results Reveal

Kamada (KMDA) has released an update.

Kamada Ltd., a global biopharmaceutical company specializing in rare and serious conditions, is set to release its financial results for the second quarter and first half of 2024 on August 14, before the U.S. market opens. The company will also host a conference call on the same day to discuss the results and address investor queries. Kamada’s diverse portfolio includes FDA-approved plasma-derived products, with a strategic focus on growth through its commercial products and ongoing research in areas with high unmet medical needs.

For further insights into KMDA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskKamada’s Strong Growth and Strategic Expansion in 2024
TheFlyKamada reports Q3 EPS 7c, consensus 7c
TheFlyKamada sees FY24 revenue $158M-$162M, consensus $160.47M
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App